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•  This is a retrospective study in which patient 
data was collected from the Tumor Registry 
Board and EHMR chart review.  
•  There were 163 charts reviewed of patients 
with HER-2/neu positive breast cancer. 
•  Patient information collected: Age, gender, 
stage of cancer, ER/PR receptor status, 
treatment modalities and 3-year survival 
outcomes. 
•  Breast cancer is the most common cancer in 
women in the United States.
•  More than 210,000 women were estimated to 
be diagnosed in 2005 in the United States and 
over 40,000 were predicted to die from the 
disease.1
•  Amplification of the HER-2/neu gene occurs in 
about 20%–25% of all breast cancers.1,3 
•  HER-2/neu breast cancer is an aggressive 
type of breast cancer that has a high rate of 
recurrence and short disease-free intervals 
after adjuvant chemotherapy.4,5 
•  Trastuzumab is a type of adjuvant therapy 
known to improve survival outcomes in 
patients with HER-2/neu positive cancer.9,10
•  HER-2/neu positive breast cancer has a poor 
prognosis compared to other types of breast 
cancer. 
•  This project investigates 3-year survival 
outcomes for patients with HER-2/neu positive 
tumors treated with adjuvant therapy in the 
LVHN system.
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Methodology
 
•  Out of 163 patients, 72 patients met the inclusion criteria. 
•  The 3-year overall survival was 35.4 months and the 3-year progression-free survival was 35 months for all 
patients (Figure 2).
•  The 3-year overall survival and progression-free survival were, respectively, 35.4 months and 35.4 months 
for Stage I cancer, 36 months and 34.9 months for Stage II cancer, and 33.7 months and 33.7 months for 
Stage III cancer (Figure 2)
•  3-year survival outcomes for patients with hormone positive disease compared to hormone negative 
disease (3-year overall survival: 35.6 months vs. 34.9 months;3-year progression-free survival: 35.8 months 
vs. 34.9 months) (Figure 3).
Results
 
•  The progression-free survival was highest in Stage 1 cancer, followed by Stage 2 and Stage 3 cancer. Both 
overall survival and progression-free survival were lowest in Stage 3 cancer. This is expected as survival 
outcomes worsen with advancing stage. Overall Survival was highest in Stage II cancer, which can be 
explained by the small sample size.
•  3-year overall survival and progression-free survival were better for patients with hormone positive disease 
compared to hormone negative disease. This is likely due to the additional effect of hormonal agents.
•  Additional research is needed to calculate 5 year survival rates to compare to national standards.
•  As a Quality Improvement Project, this initiative embodies the SELECT principles of patient centered care, 
shared decision-making and healthcare improvement.
Discussion
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Survival Outcomes in Stage I-III HER-2/neu
Positive Breast Cancer
 
•  The results of this project suggest that patients with HER-2/neu positive breast cancer who receive adjuvant 
therapy in the Lehigh Valley system  had an overall survival of 35.4 months and a progression-free survival 
of 35 months.
•  Patients with Stage II cancer had the highest overall survival and patients with Stage I cancer had the 
highest progression-free survival.
•  Patients with Stage III cancer had the lowest overall survival and progression-free survival
•  Patients with hormone positive cancer had higher overall survival and progression-free survival than those 
with hormone  negative cancer.
•  The next step will be to compare survival outcomes in patients undergoing different adjuvant treatments to 
guide oncologists at Lehigh Valley choose the best treatment regimen for their patients.
Conclusions and Future Implications
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Figure 2. Three-year overall survival and progression-free survival in patients with HER-2/neu 
positive breast cancer treated with adjuvant therapy at LVHN from 2010-2013. 
Figure 3. Three-year overall survival and progression-free survival in patients with ER+/PR + vs. 
ER-/PR- HER-2/neu positive breast cancer treated with adjuvant therapy at LVHN from 2010-2013. 
Figure 1. Consort diagram of the patient selection procedure and subgroup allocation for HER-
2/neu positive breast cancer patients from 2010-2013. 
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